[go: up one dir, main page]

Mackiewicz et al., 1995 - Google Patents

Gene Therapy of Human Melanoma. Immunization of Patients with Autologous Tumor Cells Admixed with Allogeneic Melanoma Cells Secreting Interleukin 6 and …

Mackiewicz et al., 1995

View PDF
Document ID
7562279490220966722
Author
Mackiewicz A
Gorny A
Laciak M
Malicki J
Murawa P
Nowak J
Wiznerowicz M
Hawley R
Heinrich P
Rose-John S
Publication year
Publication venue
Human Gene Therapy

External Links

Snippet

1.0 OBJECTIVES To actively immunize HLA-Al and/or HLA-A2 positive patients with irradiated autologous tumor cells admixed with HLA-AI, A2 positive allogeneic melanoma cells that have been genetically modified by transfection to secrete interleukin 6 (IL-6) and …
Continue reading at journals.sagepub.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Similar Documents

Publication Publication Date Title
US7670611B2 (en) Cancer immunotherapy with semi-allogeneic cells
Wei et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma
Gong et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells
Comes et al. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine
Rousseau et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation
Fabry et al. Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes.
Veelken et al. A phase‐I clinical study of autologous tumor cells plus interleukin‐2‐gene‐transfected allogeneic fibroblasts as a vaccine in patients with cancer
Ogawa et al. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12
Pulaski et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ
Eguchi et al. Identification of interleukin-13 receptor α2 peptide analogues capable of inducing improved antiglioma CTL responses
BRPI0815578B1 (en) cdca1 peptide, its use and immunogenic composition comprising the same to induce immunity, treat and / or prevent cancer, as well as an in vitro method to induce an antigen presenting cell and a cytotoxic t cell (killer)
Graf et al. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor
Mackiewicz et al. Gene Therapy of Human Melanoma. Immunization of Patients with Autologous Tumor Cells Admixed with Allogeneic Melanoma Cells Secreting Interleukin 6 and Soluble Interleukin 6 Receptor. University School of Medical Sciences at GreatPoland Cancer Center, Poznań, Poland
Chen et al. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Arienti et al. Interleukin-Gene-Transduced Human Melanoma Cells Efficiently Stimulate MHC-Unrestricted and MHC-Restricted Autologous Lymphocytes
Saito et al. Cloned auto-Ia-reactive T cells elicit lichen planus-like lesion in the skin of syngeneic mice.
Cayssials et al. Chronic myeloid leukemia: Immunobiology and novel immunotherapeutic approaches
Kruse et al. Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors
US20020114812A1 (en) Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
Jiang et al. HLA Tetramer–Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma
US20110165187A1 (en) Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
Kim et al. Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7. 1 and interleukin-7
US20040043040A1 (en) SDF-1 beta tumor vaccines and uses therefor
Meyer et al. Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2. 1+-matched situation
Onoé et al. Positive and negative selection of T cell repertoires during differentiation in allogeneic bone marrow chimeras